<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title> &#187; New Drugs</title>
	<atom:link href="http://pharmaexecnews.com/category/fda/new-drugs/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaexecnews.com</link>
	<description></description>
	<lastBuildDate>Fri, 29 Apr 2011 14:00:12 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Preventing Damage from Heart Attacks &amp; Strokes with an Injection</title>
		<link>http://pharmaexecnews.com/biotechnology/preventing-damage-heart-attacks-strokes-injection/</link>
		<comments>http://pharmaexecnews.com/biotechnology/preventing-damage-heart-attacks-strokes-injection/#comments</comments>
		<pubDate>Tue, 26 Apr 2011 08:00:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Cardiovascular]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[New Drugs]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11510</guid>
		<description><![CDATA[A researching team from the University of Leicester has offered the promise of a simple injection that could be developed to restrict the damage that results from heart attacks and strokes. Described by the lead researcher as &#8216;a fascinating new achievement&#8217;, work has already begun to translate the research into novel clinical therapies.

Professor Wilhelm Schwaeble [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/preventing-damage-heart-attacks-strokes-injection/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Drug Shows Unprecedented Weight Loss in Clinical Trials</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/drug-shows-unprecedented-weight-loss-clinical-trials/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/drug-shows-unprecedented-weight-loss-clinical-trials/#comments</comments>
		<pubDate>Wed, 20 Apr 2011 14:00:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11497</guid>
		<description><![CDATA[An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers at Duke University  Medical Center.

The study has found that treatment with the controlled-release combination therapy made up of phentermine and topiramate [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/drug-shows-unprecedented-weight-loss-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rate of Drug Approvals Dropping</title>
		<link>http://pharmaexecnews.com/biotechnology/rate-drug-approvals-dropping/</link>
		<comments>http://pharmaexecnews.com/biotechnology/rate-drug-approvals-dropping/#comments</comments>
		<pubDate>Thu, 17 Feb 2011 08:00:22 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11173</guid>
		<description><![CDATA[Want proof that achieving FDA approval is more difficult than in the past? A study released by the BIO and BioMedTracker that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is near one in 10. Previously the rate of approval were one [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/rate-drug-approvals-dropping/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Which Specialty Drugmakers Should Big Pharma Buy?</title>
		<link>http://pharmaexecnews.com/biotechnology/specialty-drugmakers-big-pharma-buy/</link>
		<comments>http://pharmaexecnews.com/biotechnology/specialty-drugmakers-big-pharma-buy/#comments</comments>
		<pubDate>Mon, 14 Feb 2011 08:00:23 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Deals and Mergers]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11160</guid>
		<description><![CDATA[Every so often, someone sets up a dartboard of likely targets for Big Pharma buyouts. This time, the target-setter is Barron&#8217;s, and the focus is on companies with market values of $10 billion or less. Most of them have at least one marketed product: &#8220;It&#8217;s less dangerous playing smaller outfits with approved drugs than those [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/specialty-drugmakers-big-pharma-buy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alfred Mann Doubles Down on Biotech</title>
		<link>http://pharmaexecnews.com/biotechnology/alfred-mann-doubles-biotech/</link>
		<comments>http://pharmaexecnews.com/biotechnology/alfred-mann-doubles-biotech/#comments</comments>
		<pubDate>Thu, 13 Jan 2011 08:00:37 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11068</guid>
		<description><![CDATA[As investors lay down their final bets on the FDA&#8217;s looming decision on MannKind&#8217;s Afrezza, the company&#8217;s wealthy CEO has opted to put his money where his mouth has been&#8211;doubling down on an ambitious wager that the much-maligned inhaled insulin treatment Afrezza will get a green light from regulators.

The Wall Street Journal reports that Alfred [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/alfred-mann-doubles-biotech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dry Powder Inhaler Stays Strong Even if Breath is Weak</title>
		<link>http://pharmaexecnews.com/biotechnology/dry-powder-inhaler-stays-strong-breath-weak/</link>
		<comments>http://pharmaexecnews.com/biotechnology/dry-powder-inhaler-stays-strong-breath-weak/#comments</comments>
		<pubDate>Tue, 14 Dec 2010 08:00:31 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Devices and Technology]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10970</guid>
		<description><![CDATA[MedGadget blog tells us about a new dry powder inhaler that, according to Cambridge Consultants and India&#8217;s Sun Pharma Advanced Research Company (SPARC), delivers an even drug dose deep into the lungs no matter how strong the patient&#8217;s inhalation.

The device uses a &#8220;de-agglomeration engine&#8221; to separate the drug from the lactose &#8216;carrier&#8217; particles. The companies [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/dry-powder-inhaler-stays-strong-breath-weak/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA&#8217;s Top Q4 Blockbuster Drug Decisions</title>
		<link>http://pharmaexecnews.com/biotechnology/fdas-top-q4-blockbuster-drug-decisions/</link>
		<comments>http://pharmaexecnews.com/biotechnology/fdas-top-q4-blockbuster-drug-decisions/#comments</comments>
		<pubDate>Tue, 30 Nov 2010 08:00:37 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10927</guid>
		<description><![CDATA[The FDA has some of its biggest decisions of the year looming in the next few months. The first new lupus drug in half a century, a blood-thinner with mega-blockbuster potential, controversial weight drugs and more are all up for regulatory decisions that can move markets and either throw a bucket of cold water or [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/fdas-top-q4-blockbuster-drug-decisions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amgen Proposes Key Hurdles for Biosimilar Regs</title>
		<link>http://pharmaexecnews.com/biotechnology/amgen-proposes-key-hurdles-biosimilar-regs/</link>
		<comments>http://pharmaexecnews.com/biotechnology/amgen-proposes-key-hurdles-biosimilar-regs/#comments</comments>
		<pubDate>Thu, 11 Nov 2010 08:00:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10876</guid>
		<description><![CDATA[The FDA&#8217;s marathon run toward a new set of regulations to govern the development of biosimilars is official. Regulators will host their first public meeting on follow-on drug regs, and you can expect to hear plenty from big companies like Amgen on the need for lengthy and expensive clinical trials.

As Reuters notes, the agency has [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/amgen-proposes-key-hurdles-biosimilar-regs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis to File Meningitis Vaccine for Infants</title>
		<link>http://pharmaexecnews.com/biotechnology/novartis-file-meningitis-vaccine-infants/</link>
		<comments>http://pharmaexecnews.com/biotechnology/novartis-file-meningitis-vaccine-infants/#comments</comments>
		<pubDate>Wed, 03 Nov 2010 08:00:28 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10851</guid>
		<description><![CDATA[Swiss drugmaker Novartis AG wants to file its meningitis vaccine Menveo for use in small infants in the United States and Europe after a late-stage study with children of this age group was successful.  In the phase III study, a high percentage of the 4,500 infants as young as 2 months showed the immune response [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/novartis-file-meningitis-vaccine-infants/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Parkinson’s Drug Development</title>
		<link>http://pharmaexecnews.com/biotechnology/parkinsons-drug-development/</link>
		<comments>http://pharmaexecnews.com/biotechnology/parkinsons-drug-development/#comments</comments>
		<pubDate>Tue, 02 Nov 2010 08:00:21 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Medical Research]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[Gene therapy]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10846</guid>
		<description><![CDATA[The side effects of the standard medication for Parkinson&#8217;s disease have long been a preoccupation of brain researchers. Now Daniella Rylander has presented new findings in a recently defended PhD thesis at Lund University that provide hope of more effective medication for those who suffer from the nerve cell disease.

In her thesis, neuroscience researcher Daniella [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/parkinsons-drug-development/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

